The effects of vildagliptin in addition to insulin on glycemic control in hemodialysis patients with type 2 diabetes mellitus
Not Applicable
- Conditions
- type 2 diabetes mellitus undergoing hemodialysis
- Registration Number
- JPRN-UMIN000010703
- Lead Sponsor
- Saiseikai Kumamoto Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Severe ketosis, or diabetic coma or precoma, type1 diabetes 2) Severe liver dysfunction 3) Diarrhea or vomiting 4) Severe infection, before and after surgery, or severe trauma 5) History of lactic acidosis or pancreatitis 6) Severe cardiac or pulmonary dysfunction, such as shock, heart failure, myocardial infarction, and pulmonary embolism. 7) Dehydration 8) History of severe alcoholic abuse 9) Malnutrition, starvation, debility, pituitary dysfunction, and adrenal insufficiency 10) Pregnant female, female with possibility of pregnancy 11) Malignancy 12) History of hypersensitivity to targeted medication 13) Patients inappropriate for medical reason
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total daily dose of insulin and HbA1c(NGSP) at 0, 12 and 24 weeks after administration of vildagliptin Mean amplitude of glycemic excursions Safety and adherence
- Secondary Outcome Measures
Name Time Method Events of hypoglycemia Body weight